129,749 Shares in Inozyme Pharma, Inc. (NASDAQ:INZY) Bought by Jacobs Levy Equity Management Inc.

Jacobs Levy Equity Management Inc. purchased a new stake in shares of Inozyme Pharma, Inc. (NASDAQ:INZY - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 129,749 shares of the company's stock, valued at approximately $359,000. Jacobs Levy Equity Management Inc. owned about 0.20% of Inozyme Pharma at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Barclays PLC raised its position in shares of Inozyme Pharma by 261.4% in the third quarter. Barclays PLC now owns 76,730 shares of the company's stock valued at $401,000 after purchasing an additional 55,497 shares during the period. JPMorgan Chase & Co. raised its holdings in Inozyme Pharma by 31.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 28,928 shares of the company's stock valued at $151,000 after acquiring an additional 6,851 shares during the period. China Universal Asset Management Co. Ltd. bought a new position in Inozyme Pharma in the 4th quarter valued at about $38,000. abrdn plc acquired a new stake in Inozyme Pharma during the fourth quarter worth approximately $472,000. Finally, Palumbo Wealth Management LLC boosted its holdings in shares of Inozyme Pharma by 52.3% during the fourth quarter. Palumbo Wealth Management LLC now owns 23,281 shares of the company's stock worth $64,000 after acquiring an additional 7,995 shares during the period. 88.30% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on INZY shares. Jefferies Financial Group reiterated a "hold" rating and set a $4.00 target price (down previously from $15.00) on shares of Inozyme Pharma in a research note on Friday, May 16th. Needham & Company LLC cut Inozyme Pharma from a "moderate buy" rating to a "hold" rating in a research report on Friday, May 16th. Wells Fargo & Company reissued an "equal weight" rating and issued a $4.00 target price on shares of Inozyme Pharma in a research report on Friday, May 16th. HC Wainwright reaffirmed a "buy" rating and set a $16.00 price target on shares of Inozyme Pharma in a research report on Thursday, April 10th. Finally, Raymond James lowered their price target on shares of Inozyme Pharma from $24.00 to $12.00 and set an "outperform" rating on the stock in a research report on Wednesday, March 12th. Five equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $11.75.

Inozyme Pharma Stock Performance

Shares of INZY remained flat at $3.95 during mid-day trading on Wednesday. 2,556,109 shares of the stock were exchanged, compared to its average volume of 804,782. The company has a market cap of $255.02 million, a P/E ratio of -2.53 and a beta of 1.35. The company has a quick ratio of 7.68, a current ratio of 7.68 and a debt-to-equity ratio of 0.51. The business's fifty day moving average price is $1.21 and its 200 day moving average price is $1.87. Inozyme Pharma, Inc. has a one year low of $0.72 and a one year high of $6.24.

Inozyme Pharma (NASDAQ:INZY - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.44) EPS for the quarter, missing analysts' consensus estimates of ($0.43) by ($0.01). As a group, equities analysts forecast that Inozyme Pharma, Inc. will post -1.59 earnings per share for the current fiscal year.

Inozyme Pharma Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.